Comparison of next Generation Sequencing Technologies for the Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes
暂无分享,去创建一个
P. Klenerman | P. Simmonds | D. Bonsall | R. Bowden | Camilla L. C. Ip | R. Myers | E. Barnes | Sunando Roy | J. Bryant | J. Breuer | S. Vattipally | J. McLauchlan | C. Hinds | A. Trebes | P. Piazza | M. Ansari | A. da Silva Filipe | D. Bonsall | V. Sreenu | E. Hudson | E. Thomson | W. Adamson | J. Witteveldt | M. Christiansen | J. Mbisa | Kieren T. Lythgow | A. L. Brown | D. Bibby | A. Ansari | A. Filipe | A. Badhan | Alexander Brown | A. Brown | Paolo Piazza | E. Barnes | Emma Hudson
[1] Christopher Ruis,et al. Norovirus Whole-Genome Sequencing by SureSelect Target Enrichment: a Robust and Sensitive Method , 2016, Journal of Clinical Microbiology.
[2] J. Rockstroh,et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison , 2015, BMC Infectious Diseases.
[3] M. Imamura,et al. Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy , 2015, Journal of medical virology.
[4] David Bonsall,et al. ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens , 2015, F1000Research.
[5] L. Naeger,et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir , 2015, Hepatology.
[6] A. Flaxman,et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.
[7] J. Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.
[8] Oliver Lenz,et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial , 2014, The Lancet.
[9] Riina Salupere,et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.
[10] H. Mo,et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.
[11] E. Thomson,et al. Mixed Genotype Hepatitis C Infections and Implications for Treatment , 2014, Hepatology.
[12] C. Rice,et al. Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.
[13] L. McIntyre,et al. Consistent Errors in First Strand cDNA Due to Random Hexamer Mispriming , 2013, PloS one.
[14] T. Hassanein,et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial , 2013, The Lancet.
[15] J. V. D. van der Meer,et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM , 2011, AIDS.
[16] P. Klenerman,et al. Dynamic coinfection with multiple viral subtypes in acute hepatitis C. , 2010, The Journal of infectious diseases.
[17] P. Klapper,et al. Planning for the healthcare burden of hepatitis C infection: Hepatitis C genotypes identified in England, 2002-2007. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[18] H. Blum,et al. [Molecular virology of hepatitis C]. , 2002, Praxis.
[19] A. Creutzig,et al. [Clinical evidence]. , 2001, VASA. Zeitschrift fur Gefasskrankheiten.
[20] M. Major,et al. The molecular virology of hepatitis C , 1997, Hepatology.
[21] A. Weiner,et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution , 1992, Journal of virology.